Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 54

1.

MicroRNA regulation of oncolytic herpes simplex virus-1 for selective killing of prostate cancer cells.

Lee CY, Rennie PS, Jia WW.

Clin Cancer Res. 2009 Aug 15;15(16):5126-35. doi: 10.1158/1078-0432.CCR-09-0051. Epub 2009 Aug 11.

2.

MicroRNAs and glioblastoma; the stem cell connection.

Godlewski J, Newton HB, Chiocca EA, Lawler SE.

Cell Death Differ. 2010 Feb;17(2):221-8. doi: 10.1038/cdd.2009.71. Epub 2009 Jun 12. Review.

3.

MicroRNA-mediated species-specific attenuation of influenza A virus.

Perez JT, Pham AM, Lorini MH, Chua MA, Steel J, tenOever BR.

Nat Biotechnol. 2009 Jun;27(6):572-6. doi: 10.1038/nbt.1542. Epub 2009 May 31.

PMID:
19483680
4.

Use of tissue-specific microRNA to control pathology of wild-type adenovirus without attenuation of its ability to kill cancer cells.

Cawood R, Chen HH, Carroll F, Bazan-Peregrino M, van Rooijen N, Seymour LW.

PLoS Pathog. 2009 May;5(5):e1000440. doi: 10.1371/journal.ppat.1000440. Epub 2009 May 22.

5.

Biological basis for restriction of microRNA targets to the 3' untranslated region in mammalian mRNAs.

Gu S, Jin L, Zhang F, Sarnow P, Kay MA.

Nat Struct Mol Biol. 2009 Feb;16(2):144-50. doi: 10.1038/nsmb.1552. Epub 2009 Feb 1.

6.

MicroRNAs and the regulation of vector tropism.

Kelly EJ, Russell SJ.

Mol Ther. 2009 Mar;17(3):409-16. doi: 10.1038/mt.2008.288. Epub 2008 Dec 23. Review.

7.

Stable knockdown of microRNA in vivo by lentiviral vectors.

Gentner B, Schira G, Giustacchini A, Amendola M, Brown BD, Ponzoni M, Naldini L.

Nat Methods. 2009 Jan;6(1):63-6. doi: 10.1038/nmeth.1277. Epub 2008 Nov 30.

PMID:
19043411
8.

MicroRNA profiling as a tool to understand prognosis, therapy response and resistance in breast cancer.

Iorio MV, Casalini P, Tagliabue E, Ménard S, Croce CM.

Eur J Cancer. 2008 Dec;44(18):2753-9. doi: 10.1016/j.ejca.2008.09.037. Epub 2008 Nov 18. Review.

PMID:
19022662
9.

Dengue virus regulates type I interferon signalling in a strain-dependent manner in human cell lines.

Umareddy I, Tang KF, Vasudevan SG, Devi S, Hibberd ML, Gu F.

J Gen Virol. 2008 Dec;89(Pt 12):3052-62. doi: 10.1099/vir.0.2008/001594-0.

PMID:
19008393
10.

Synergistic antitumor effects of transarterial viroembolization for multifocal hepatocellular carcinoma in rats.

Altomonte J, Braren R, Schulz S, Marozin S, Rummeny EJ, Schmid RM, Ebert O.

Hepatology. 2008 Dec;48(6):1864-73. doi: 10.1002/hep.22546.

PMID:
19003878
11.

Engineering microRNA responsiveness to decrease virus pathogenicity.

Kelly EJ, Hadac EM, Greiner S, Russell SJ.

Nat Med. 2008 Nov;14(11):1278-83. doi: 10.1038/nm.1776. Epub 2008 Oct 26.

PMID:
18953352
12.

Use of biological therapy to enhance both virotherapy and adoptive T-cell therapy for cancer.

Kottke T, Diaz RM, Kaluza K, Pulido J, Galivo F, Wongthida P, Thompson J, Willmon C, Barber GN, Chester J, Selby P, Strome S, Harrington K, Melcher A, Vile RG.

Mol Ther. 2008 Dec;16(12):1910-8. doi: 10.1038/mt.2008.212. Epub 2008 Sep 30.

13.

Generation of a conditionally replicating adenovirus based on targeted destruction of E1A mRNA by a cell type-specific MicroRNA.

Ylösmäki E, Hakkarainen T, Hemminki A, Visakorpi T, Andino R, Saksela K.

J Virol. 2008 Nov;82(22):11009-15. doi: 10.1128/JVI.01608-08. Epub 2008 Sep 17.

14.

Harnessing endogenous miRNAs to control virus tissue tropism as a strategy for developing attenuated virus vaccines.

Barnes D, Kunitomi M, Vignuzzi M, Saksela K, Andino R.

Cell Host Microbe. 2008 Sep 11;4(3):239-48. doi: 10.1016/j.chom.2008.08.003.

15.

A let-7 MicroRNA-sensitive vesicular stomatitis virus demonstrates tumor-specific replication.

Edge RE, Falls TJ, Brown CW, Lichty BD, Atkins H, Bell JC.

Mol Ther. 2008 Aug;16(8):1437-43. doi: 10.1038/mt.2008.130. Epub 2008 Jun 17.

16.

Oncolytic vesicular stomatitis viruses are potent agents for intravesical treatment of high-risk bladder cancer.

Hadaschik BA, Zhang K, So AI, Fazli L, Jia W, Bell JC, Gleave ME, Rennie PS.

Cancer Res. 2008 Jun 15;68(12):4506-10. doi: 10.1158/0008-5472.CAN-08-0238.

17.

Systemic vesicular stomatitis virus selectively destroys multifocal glioma and metastatic carcinoma in brain.

Ozduman K, Wollmann G, Piepmeier JM, van den Pol AN.

J Neurosci. 2008 Feb 20;28(8):1882-93. doi: 10.1523/JNEUROSCI.4905-07.2008.

18.

Endogenous microRNA can be broadly exploited to regulate transgene expression according to tissue, lineage and differentiation state.

Brown BD, Gentner B, Cantore A, Colleoni S, Amendola M, Zingale A, Baccarini A, Lazzari G, Galli C, Naldini L.

Nat Biotechnol. 2007 Dec;25(12):1457-67. Epub 2007 Nov 16.

PMID:
18026085
19.

MyD88 protects from lethal encephalitis during infection with vesicular stomatitis virus.

Lang KS, Navarini AA, Recher M, Lang PA, Heikenwalder M, Stecher B, Bergthaler A, Odermatt B, Akira S, Honda K, Hengartner H, Zinkernagel RM.

Eur J Immunol. 2007 Sep;37(9):2434-40.

20.

Hypersusceptibility to vesicular stomatitis virus infection in Dicer1-deficient mice is due to impaired miR24 and miR93 expression.

Otsuka M, Jing Q, Georgel P, New L, Chen J, Mols J, Kang YJ, Jiang Z, Du X, Cook R, Das SC, Pattnaik AK, Beutler B, Han J.

Immunity. 2007 Jul;27(1):123-34. Epub 2007 Jul 5.

Supplemental Content

Support Center